Cargando…

Increased plasma and brain immunoglobulin A in Alzheimer’s disease is lost in apolipoprotein E ε4 carriers

BACKGROUND: Alzheimer’s disease (AD) is foremost characterized by β-amyloid (Aβ)-extracellular plaques, tau-intraneuronal fibrillary tangles (NFT), and neuroinflammation, but over the last years it has become evident that peripheral inflammation might also contribute to the disease. AD patients ofte...

Descripción completa

Detalles Bibliográficos
Autores principales: Pocevičiūtė, Dovilė, Nuñez-Diaz, Cristina, Roth, Bodil, Janelidze, Shorena, Giannisis, Andreas, Hansson, Oskar, Wennström, Malin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414424/
https://www.ncbi.nlm.nih.gov/pubmed/36008818
http://dx.doi.org/10.1186/s13195-022-01062-z
_version_ 1784775983903014912
author Pocevičiūtė, Dovilė
Nuñez-Diaz, Cristina
Roth, Bodil
Janelidze, Shorena
Giannisis, Andreas
Hansson, Oskar
Wennström, Malin
author_facet Pocevičiūtė, Dovilė
Nuñez-Diaz, Cristina
Roth, Bodil
Janelidze, Shorena
Giannisis, Andreas
Hansson, Oskar
Wennström, Malin
author_sort Pocevičiūtė, Dovilė
collection PubMed
description BACKGROUND: Alzheimer’s disease (AD) is foremost characterized by β-amyloid (Aβ)-extracellular plaques, tau-intraneuronal fibrillary tangles (NFT), and neuroinflammation, but over the last years it has become evident that peripheral inflammation might also contribute to the disease. AD patients often demonstrate increased levels of circulating proinflammatory mediators and altered antibody levels in the blood. In our study, we investigated the plasma Immunoglobulin A (IgA) levels in association with apolipoprotein E (APOE) ε4 status and Aβ pathology. METHODS: IgA levels in antemortem-collected (cohort I) and postmortem-collected (cohort II) plasma samples from AD patients (n = 30 in cohort I and n = 16 in cohort II) and non-demented age-matched controls (NC) (n = 42 in cohort I and n = 7 in cohort II) were measured using ELISA. Hippocampal sections from cohort II were immunostained against IgA, and the IgA area fraction as well as the number of IgA positive (IgA+) cells in the cornu ammonis region were analysed using ImageJ. The relationship between plasma IgA levels and cognition, C-reactive protein (CRP), and cerebrospinal fluid (CSF) AD biomarkers in cohort I as well as neuropathology, IgA+ cell number, and IgA area fraction in cohort II was analysed before and after grouping the cohorts into APOEε4 carriers and APOEε4 non-carriers. RESULTS: Plasma IgA levels were higher in AD patients compared to NC in both cohorts. Also, AD patients demonstrated higher IgA area fraction and IgA+ cell number compared to NC. When APOEε4 status was considered, higher plasma IgA levels in AD patients were only seen in APOEε4 non-carriers. Finally, plasma IgA levels, exclusively in APOEε4 non-carriers, were associated with cognition, CRP, and CSF Aβ levels in cohort I as well as with IgA area fraction, IgA+ cell number, and Aβ, Lewy body, and NFT neuropathology in cohort II. CONCLUSIONS: Our study suggests that AD pathology and cognitive decline are associated with increased plasma IgA levels in an APOE allele-dependent manner, where the associations are lost in APOEε4 carriers. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13195-022-01062-z.
format Online
Article
Text
id pubmed-9414424
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-94144242022-08-27 Increased plasma and brain immunoglobulin A in Alzheimer’s disease is lost in apolipoprotein E ε4 carriers Pocevičiūtė, Dovilė Nuñez-Diaz, Cristina Roth, Bodil Janelidze, Shorena Giannisis, Andreas Hansson, Oskar Wennström, Malin Alzheimers Res Ther Research BACKGROUND: Alzheimer’s disease (AD) is foremost characterized by β-amyloid (Aβ)-extracellular plaques, tau-intraneuronal fibrillary tangles (NFT), and neuroinflammation, but over the last years it has become evident that peripheral inflammation might also contribute to the disease. AD patients often demonstrate increased levels of circulating proinflammatory mediators and altered antibody levels in the blood. In our study, we investigated the plasma Immunoglobulin A (IgA) levels in association with apolipoprotein E (APOE) ε4 status and Aβ pathology. METHODS: IgA levels in antemortem-collected (cohort I) and postmortem-collected (cohort II) plasma samples from AD patients (n = 30 in cohort I and n = 16 in cohort II) and non-demented age-matched controls (NC) (n = 42 in cohort I and n = 7 in cohort II) were measured using ELISA. Hippocampal sections from cohort II were immunostained against IgA, and the IgA area fraction as well as the number of IgA positive (IgA+) cells in the cornu ammonis region were analysed using ImageJ. The relationship between plasma IgA levels and cognition, C-reactive protein (CRP), and cerebrospinal fluid (CSF) AD biomarkers in cohort I as well as neuropathology, IgA+ cell number, and IgA area fraction in cohort II was analysed before and after grouping the cohorts into APOEε4 carriers and APOEε4 non-carriers. RESULTS: Plasma IgA levels were higher in AD patients compared to NC in both cohorts. Also, AD patients demonstrated higher IgA area fraction and IgA+ cell number compared to NC. When APOEε4 status was considered, higher plasma IgA levels in AD patients were only seen in APOEε4 non-carriers. Finally, plasma IgA levels, exclusively in APOEε4 non-carriers, were associated with cognition, CRP, and CSF Aβ levels in cohort I as well as with IgA area fraction, IgA+ cell number, and Aβ, Lewy body, and NFT neuropathology in cohort II. CONCLUSIONS: Our study suggests that AD pathology and cognitive decline are associated with increased plasma IgA levels in an APOE allele-dependent manner, where the associations are lost in APOEε4 carriers. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13195-022-01062-z. BioMed Central 2022-08-26 /pmc/articles/PMC9414424/ /pubmed/36008818 http://dx.doi.org/10.1186/s13195-022-01062-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Pocevičiūtė, Dovilė
Nuñez-Diaz, Cristina
Roth, Bodil
Janelidze, Shorena
Giannisis, Andreas
Hansson, Oskar
Wennström, Malin
Increased plasma and brain immunoglobulin A in Alzheimer’s disease is lost in apolipoprotein E ε4 carriers
title Increased plasma and brain immunoglobulin A in Alzheimer’s disease is lost in apolipoprotein E ε4 carriers
title_full Increased plasma and brain immunoglobulin A in Alzheimer’s disease is lost in apolipoprotein E ε4 carriers
title_fullStr Increased plasma and brain immunoglobulin A in Alzheimer’s disease is lost in apolipoprotein E ε4 carriers
title_full_unstemmed Increased plasma and brain immunoglobulin A in Alzheimer’s disease is lost in apolipoprotein E ε4 carriers
title_short Increased plasma and brain immunoglobulin A in Alzheimer’s disease is lost in apolipoprotein E ε4 carriers
title_sort increased plasma and brain immunoglobulin a in alzheimer’s disease is lost in apolipoprotein e ε4 carriers
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414424/
https://www.ncbi.nlm.nih.gov/pubmed/36008818
http://dx.doi.org/10.1186/s13195-022-01062-z
work_keys_str_mv AT poceviciutedovile increasedplasmaandbrainimmunoglobulinainalzheimersdiseaseislostinapolipoproteinee4carriers
AT nunezdiazcristina increasedplasmaandbrainimmunoglobulinainalzheimersdiseaseislostinapolipoproteinee4carriers
AT rothbodil increasedplasmaandbrainimmunoglobulinainalzheimersdiseaseislostinapolipoproteinee4carriers
AT janelidzeshorena increasedplasmaandbrainimmunoglobulinainalzheimersdiseaseislostinapolipoproteinee4carriers
AT increasedplasmaandbrainimmunoglobulinainalzheimersdiseaseislostinapolipoproteinee4carriers
AT giannisisandreas increasedplasmaandbrainimmunoglobulinainalzheimersdiseaseislostinapolipoproteinee4carriers
AT hanssonoskar increasedplasmaandbrainimmunoglobulinainalzheimersdiseaseislostinapolipoproteinee4carriers
AT wennstrommalin increasedplasmaandbrainimmunoglobulinainalzheimersdiseaseislostinapolipoproteinee4carriers